Pharsight

1. List of Eliquis drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6967208	BRISTOL MYERS SQUIBB	Lactam-containing compounds and derivatives thereof as factor Xa inhibitors	Nov, 2026 (3 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9326945	BRISTOL MYERS SQUIBB	Apixaban formulations	Feb, 2031 (8 years from now)

Drugs and Companies using APIXABAN ingredient

Market Authorisation Date: 28 December, 2012

Treatment: Prophylaxis of deep vein thrombosis and pulmonary embolism; Reducing the risk of stroke and systemic embolism; Treatment of pulmonary embolism (pe); Reduce the risk of recurrent deep vein thrombosis (dvt); Treatment of deep vein thrombosis (dvt); Reduce the risk of recurrent pulmonary embolism; Prophylaxis of deep vein thrombosis (dvt); Reducing the risk of stroke; Prophylaxis of pulmonary embolism

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
2.5 mg and 5 mg	28 Dec, 2016	25	23 Dec, 2019	24 Feb, 2031	Eligible

Strength	Dosage	Availability
2.5MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription

2. List of Sprycel drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7491725	BRISTOL MYERS SQUIBB	Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors	Mar, 2026 (3 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8680103	BRISTOL MYERS SQUIBB	Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors	Feb, 2025 (2 years from now)
US8680103 (Pediatric)	BRISTOL MYERS SQUIBB	Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors	Aug, 2025 (2 years from now)
US7491725 (Pediatric)	BRISTOL MYERS SQUIBB	Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors	Sep, 2026 (3 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Dec 21, 2025
Pediatric Exclusivity (PED)	May 9, 2025

Drugs and Companies using DASATINIB ingredient

Market Authorisation Date: 28 June, 2006

Treatment: NA

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
80 mg and 140 mg	17 Jun, 2011	1	23 Nov, 2021	28 Mar, 2026	Non-Forfeiture
20 mg, 50 mg, 70 mg and 100 mg	28 Jun, 2010	1	10 Jun, 2016	28 Mar, 2026	Non-Forfeiture Deferred

Strength	Dosage	Availability
20MG	TABLET;ORAL	Prescription
50MG	TABLET;ORAL	Prescription
70MG	TABLET;ORAL	Prescription
80MG	TABLET;ORAL	Prescription
100MG	TABLET;ORAL	Prescription
140MG	TABLET;ORAL	Prescription

3. List of Zerit Xr drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7135465	BRISTOL MYERS SQUIBB	Sustained release beadlets containing stavudine	Feb, 2023 (14 days from now)
US7135465 (Pediatric)	BRISTOL MYERS SQUIBB	Sustained release beadlets containing stavudine	Aug, 2023 (6 months from now)

Drugs and Companies using STAVUDINE ingredient

Market Authorisation Date: 31 December, 2002

Treatment: Method for treating hiv-1 infection

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
37.5MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
50MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
75MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
100MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued